Clinical trial
Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With…
NCT00408499 · University of California, Davis, Other · Completed
Key facts
| NCT number | NCT00408499 |
|---|---|
| Title | Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer |
| Official title | Phase I/II Study of Erlotinib (TARCEVA) and Cetuximab (ERBITUX) in Advanced Solid Tumors, With Emphasis on Non Small Cell Lung Cancer (NSCLC) |
| Lead sponsor | University of California, Davis, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | cetuximab, erlotinib |
| Enrollment | 64 |
| Start date | Aug 1, 2006 |
| Primary completion | Apr 1, 2009 |
| Completion | Jan 1, 2013 |
| First posted | Dec 7, 2006 |
| Last update posted | May 8, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: